Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $190,884.30 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total value of $190,884.30. Following the sale, the chief financial officer directly owned 86,669 shares in the company, valued at $1,967,386.30. This trade represents a 8.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Howard Horn also recently made the following trade(s):

• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.40, for a total value of $36,624.00.
• On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $23.56, for a total value of $72,117.16.
• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $36.38, for a total value of $112,086.78.

Ultragenyx Pharmaceutical Stock Down 1.6%

Ultragenyx Pharmaceutical stock opened at $21.46 on Friday. The firm has a market capitalization of $2.07 billion, a PE ratio of -3.67 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $42.37. The firm’s 50-day simple moving average is $23.30 and its 200 day simple moving average is $29.14.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s revenue was up 25.5% compared to the same quarter last year. During the same quarter last year, the business posted ($1.39) earnings per share. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in the business. Assetmark Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares during the last quarter. Huntington National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $39,000. Smartleaf Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RARE has been the topic of a number of recent research reports. Barclays reduced their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Bank of America cut their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Canaccord Genuity Group decreased their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Robert W. Baird dropped their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Finally, Wedbush reissued a “neutral” rating and issued a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $68.29.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Regulatory/procedural deadline — multiple firms are reminding eligible purchasers of the April 6, 2026 lead plaintiff deadline for the class action; this is a procedural notice but focuses attention on potential litigation exposure. ROSEN Deadline Notice
• Negative Sentiment: Class action filings and widespread solicitations — multiple law firms (Pomerantz, Robbins Geller, ClaimsFiler, Bronstein Gewirtz & others) have circulated notices and at least one suit has been filed alleging misstatements/omissions tied to setrusumab results; that raises potential legal and financial risk. Pomerantz Notice
• Negative Sentiment: Legal overhang amplified by media/legal alerts — additional reminders from ClaimsFiler, Robbins LLP, Furuqi & Furuqi and others increase publicity around the suit and the potential damages/settlement risk. ClaimsFiler Alert
• Negative Sentiment: Prior clinical setback cited by plaintiff counsel — Levi & Korsinsky highlights the company’s >40% decline after a Phase III setrusumab failure disclosure, framing the litigation narrative and reinforcing investor concern about program and disclosure risk. Levi & Korsinsky Alert
• Negative Sentiment: Insider selling — CFO Howard Horn disclosed multiple recent sales (including March 3 sale of 1,635 shares), feeding short‑term sentiment pressure even if not necessarily signaling company fundamentals. Insider Trades Report

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.